The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space
-
Published:2018-08-27
Issue:10
Volume:24
Page:1611-1624
-
ISSN:1078-8956
-
Container-title:Nature Medicine
-
language:en
-
Short-container-title:Nat Med
Author:
Klughammer Johanna, Kiesel Barbara, Roetzer Thomas, Fortelny Nikolaus, Nemc Amelie, Nenning Karl-Heinz, Furtner Julia, Sheffield Nathan C., Datlinger Paul, Peter Nadine, Nowosielski Martha, Augustin Marco, Mischkulnig Mario, Ströbel Thomas, Alpar Donat, Ergüner Bekir, Senekowitsch Martin, Moser Patrizia, Freyschlag Christian F., Kerschbaumer Johannes, Thomé Claudius, Grams Astrid E., Stockhammer Günther, Kitzwoegerer Melitta, Oberndorfer Stefan, Marhold Franz, Weis Serge, Trenkler Johannes, Buchroithner Johanna, Pichler Josef, Haybaeck Johannes, Krassnig Stefanie, Mahdy Ali Kariem, von Campe Gord, Payer Franz, Sherif Camillo, Preiser Julius, Hauser Thomas, Winkler Peter A., Kleindienst Waltraud, Würtz Franz, Brandner-Kokalj Tanisa, Stultschnig Martin, Schweiger Stefan, Dieckmann Karin, Preusser Matthias, Langs Georg, Baumann Bernhard, Knosp Engelbert, Widhalm Georg, Marosi Christine, Hainfellner Johannes A., Woehrer Adelheid, Bock ChristophORCID
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference86 articles.
1. Ferlay, J. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer http://globocan.iarc.fr (2013). 2. Woehrer, A., Bauchet, L. & Barnholtz-Sloan, J. S. Glioblastoma survival: has it improved? Evidence from population-based studies. Curr. Opin. Neurol. 27, 666–674 (2014). 3. Chinot, O. L. et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709–722 (2014). 4. Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699–708 (2014). 5. Stupp, R. et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1100–1108 (2014).
Cited by
230 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|